Follicular Lymphoma: Clinical Trials

120 trials for Follicular Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

38 completed, 22 terminated, 21 active not recruiting, 20 recruiting. 120 Phase 1, 45 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1120Completed 38, Terminated 22, Active not recruiting 21, Recruiting 20, Unknown 9, Withdrawn 6, Not yet recruiting 3, Enrolling by invitation 1
Phase 245Completed 12, Active not recruiting 11, Terminated 8, Recruiting 7, Unknown 4, Withdrawn 3

Follow Follicular Lymphoma: new trials by email Literature Review of Follicular Lymphoma trials Research Report on Follicular Lymphoma

Trials (filtered) newest first · largest first

All 120 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI.
CAR-T anti-CD19 COL01 - Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies
Phase 1Not yet recruitingGUSTAVO SALGUERO122027-04-012026-10-20
A Trial of FHD-286 Plus Mosunetuzumab in Previously Treated Follicular Lymphoma
Mosunetuzumab, FHD-286 - Follicular Lymphoma
Phase 1Not yet recruitingWeill Medical College of Cornell University222026-11-012026-11-17
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Allogeneic NK cells, Rituximab, Tafasitamab - Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma
Phase 1RecruitingPaolo Caimi, MD152026-09-012026-09-09
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
LY4584180, Rituximab - Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell
Phase 1RecruitingEli Lilly and Company4602026-04-172026-11-04
JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma
JWCAR239, Fludarabine, Cyclophosphamide - B-Cell Non-Hodgkin Lymphoma, Large B Cell Diffuse Lymphoma
Phase 1Not yet recruitingPeking University Cancer Hospital & Institute202025-07-012025-06-17
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101 - B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
Phase 1 / Phase 2RecruitingVironexis Biotherapeutics Inc.322025-05-302026-10-26
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Pirtobrutinib, LV20.19 CAR T cells - Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
Phase 1RecruitingMedical College of Wisconsin122025-02-062026-08-06
SynKIR-310 for Relapsed/Refractory B-NHL
SynKIR-310 - B Cell Lymphoma, NHL, Adult
Phase 1RecruitingVerismo Therapeutics362024-11-012026-04-14
CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
CD19.20.22 CAR T cells, Fludarabine and Cyclophosphamide - B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL)
Phase 1Enrolling by invitationUniversity of Maryland, Baltimore152024-10-282026-09-14
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
CD22CART Infusion - Follicular Lymphoma, Mantle Cell Lymphoma
Phase 1RecruitingStanford University1482024-03-292026-08-12
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
CD79b-19 CAR T cells, Cyclophosphamide, Fludarabine - Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma
Phase 1RecruitingMarcela V. Maus, M.D.,Ph.D.242023-10-262026-10-09
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
ONM-501, Cemiplimab - Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma
Phase 1RecruitingOncoNano Medicine, Inc.1682023-10-132025-12-24
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
Tazemetostat Pill - Follicular Lymphoma, B-Cell Lymphoma
Phase 1Active not recruitingWeill Medical College of Cornell University152023-10-042026-06-17
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
IKS03 - B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
Phase 1RecruitingIksuda Therapeutics Ltd.1402023-09-052026-11-03
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Docirbrutinib - B-cell Malignancy, Chronic Lymphocytic Leukemia
Phase 1RecruitingCarna Biosciences, Inc.1202023-08-012025-12-10
Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma
lenalidomide, rituximab, parsaclisib - Follicular Lymphoma
Phase 1WithdrawnInnovent Biologics (Suzhou) Co. Ltd.2023-07-282023-10-17
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
Venetoclax, Tazemetostat - Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma
Phase 1TerminatedWeill Medical College of Cornell University32023-06-072026-04-02
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
ABBV-319 - Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia
Phase 1Active not recruitingAbbVie392023-04-262026-08-28
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
SYNCAR-001, STK-009, Cyclophosphamide - CLL/SLL, NHL
Phase 1Active not recruitingSynthekine362023-04-232026-07-10
Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers
BR1733 - Advanced Cancer, Follicular Lymphoma
Phase 1 / Phase 2UnknownShanghai Blueray Biopharma Co., Ltd.1912023-04-192024-08-07

Showing 20 of 120. Sign in to see all of them.

Narrower conditions

Lymphoma, Follicular (120)  ·  Lymphoma, Mantle-Cell (67)  ·  Lymphoma, Large B-Cell, Diffuse (66)  ·  Lymphoma, B-Cell, Marginal Zone (51)  ·  Lymphoma, Non-Hodgkin (45)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (40)  ·  Lymphoma (22)  ·  Lymphoma, B-Cell (22)  ·  Waldenstrom Macroglobulinemia (15)  ·  Burkitt Lymphoma (14)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (10)  ·  Recurrence (9)  ·  Lymphoma, T-Cell, Peripheral (6)  ·  Neoplasms (6)  ·  Hodgkin Disease (5)

Broader conditions

Hemic and Lymphatic Diseases (120)  ·  Immune System Diseases (119)  ·  Immunoproliferative Disorders (119)  ·  Lymphatic Diseases (119)  ·  Lymphoproliferative Disorders (119)  ·  Neoplasms by Histologic Type (119)  ·  Neoplasms (114)  ·  Lymphoma (98)  ·  Lymphoma, Non-Hodgkin (75)  ·  Lymphoma, B-Cell (69)  ·  Hematologic Diseases (52)  ·  Disease Attributes (46)  ·  Pathologic Processes (46)  ·  Pathological Conditions, Signs and Symptoms (46)  ·  Leukemia (42)

Interventions

Rituximab (23)  ·  Cyclophosphamide (20)  ·  fludarabine (13)  ·  Lenalidomide (9)  ·  Bendamustine Hydrochloride (8)  ·  Vincristine (7)  ·  obinutuzumab (7)  ·  venetoclax (7)  ·  Doxorubicin (6)  ·  Prednisone (6)  ·  tazemetostat (5)  ·  Gemcitabine (4)  ·  fludarabine phosphate (4)  ·  Antigens, CD19 (3)  ·  Immunotherapy, Adoptive (3)

Sponsors

National Cancer Institute (NCI) (5)  ·  Gilead Sciences (4)  ·  PersonGen BioTherapeutics (Suzhou) Co., Ltd. (4)  ·  Weill Medical College of Cornell University (4)  ·  Dana-Farber Cancer Institute (3)  ·  Genmab (3)  ·  Memorial Sloan Kettering Cancer Center (3)  ·  BeOne Medicines (2)  ·  Hoffmann-La Roche (2)  ·  M.D. Anderson Cancer Center (2)  ·  Masonic Cancer Center, University of Minnesota (2)  ·  Massachusetts General Hospital (2)  ·  Medical College of Wisconsin (2)  ·  Merck Sharp & Dohme LLC (2)  ·  Nordic Nanovector (2)

Countries

United States (85)  ·  Australia (17)  ·  China (14)  ·  Spain (14)  ·  France (13)  ·  Italy (11)  ·  Canada (8)  ·  South Korea (7)  ·  United Kingdom (7)  ·  Germany (6)  ·  Japan (6)  ·  Belgium (5)  ·  Czechia (4)  ·  Denmark (4)  ·  Netherlands (4)

Top investigators

Eliza Hawkes, MD (2)  ·  Jeremy Abramson, MD (2)  ·  Nirav Shah, MD (2)  ·  Alexey V Danilov (1)  ·  Anastasios Stathis, MD (1)  ·  Arturo Molina, MD (1)  ·  Baijun Fang, Prof. (1)  ·  Caitlin K Gribbin, M.D. (1)

Results publications

PMID 34515338, PMID 34398557, PMID 22535574, PMID 25145344, PMID 26248505, PMID 27354476, PMID 28054442, PMID 28490569, PMID 30935953, PMID 30937889, PMID 31110096, PMID 31395089, PMID 31609651, PMID 32122924, PMID 32286905, PMID 32556281, PMID 32705923, PMID 32770353, PMID 32856068, PMID 32871584, PMID 32877524, PMID 32888407, PMID 33196921, PMID 33236943, PMID 33720336, PMID 33904895, PMID 33970454, PMID 34125421, PMID 34309174, PMID 34310745, PMID 34493319, PMID 34615723, PMID 34687939, PMID 35156195, PMID 35244520, PMID 35337365, PMID 35537101, PMID 35538512, PMID 35597752, PMID 35610089, PMID 36398795, PMID 36536403, PMID 36755418, PMID 37295816, PMID 37467318, PMID 37481608, PMID 37486616, PMID 37851072, PMID 37890149, PMID 37930156

NIH funding

2017 (3), 2016 (2), 2019 (2), 2014 (1), 2018 (1), 2023 (1), 2025 (1), P30CA016672 (1), P30CA033572 (1), R01CA193140 (1), UL1TR002240 (1)